INFINIMMUNE
LIVE

Serial Number

97827376

Owner

Infinimmune, Inc.

Attorney

Aaron D. Hendelman

Filing Date

Mar 7, 2023

Add to watchlist:

No watchlists yet
View on USPTO

INFINIMMUNE Trademark

Serial Number: 97827376

INFINIMMUNE is a trademark filed by Infinimmune, Inc. on March 7, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

Infinimmune, Inc. (4 trademarks)

1600 Harbor Bay Parkway, Suite 150
Alameda, CA 94502

Entity Type: 03

Trademark Details

Filing Date

March 7, 2023

Registration Date

Not Registered

Published for Opposition

April 30, 2024

Goods & Services

downloadable computer software for the visualization and analysis of biological data for biomolecular research and the design and engineering of biomolecular products; downloadable computer software in the field of drug design and development

pharmaceutical preparations featuring antibodies for medical purposes for the treatment of autoimmune diseases, cardiovascular disease, central nervous system diseases and disorders, endocrine disorders, gastrointestinal diseases, genetic diseases and disorders, infectious diseases, inflammatory diseases, kidney disease, liver disease, metabolic diseases and disorders, musculoskeletal disorders, neurodegenerative diseases and disorders, neurological diseases and disorders, neuromuscular and viral diseases and disorders, blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations with protein expression for the treatment of autoimmune diseases, cardiovascular disease, central nervous system diseases and disorders, endocrine disorders, gastrointestinal diseases, genetic diseases and disorders, infectious diseases, inflammatory diseases, kidney disease, liver disease, metabolic diseases and disorders, musculoskeletal disorders, neurodegenerative diseases and disorders, neurological diseases and disorders, neuromuscular and viral diseases and disorders, blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes

providing medical services and medical information in the fields of immunology, single cell technologies, protein engineering, computational biology, genome assembly and DNA sequencing

medical research and development in the fields of immunology, single cell technologies, protein engineering, computational biology, genome assembly and DNA sequencing and scientific research and development; medical research and development and scientific research and development in the fields of immunology, single cell technologies, protein engineering, computational biology, genome assembly and DNA sequencing; pharmaceutical drug development services; providing temporary use of online non-downloadable software for the visualization and analysis of biological data for biomolecular research and the design and engineering of biomolecular products; providing temporary use of online non-downloadable software in the field of drug design and development

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 24, 2026 EXRA
SOU EXTENSION 4 GRANTED
Jun 23, 2026 EX4G
SOU EXTENSION 4 FILED
Jun 23, 2026 EXT4
SOU TEAS EXTENSION RECEIVED
Jun 23, 2026 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 19, 2025 EXRA
SOU EXTENSION 3 GRANTED
Dec 18, 2025 EX3G
SOU EXTENSION 3 FILED
Dec 18, 2025 EXT3
SOU TEAS EXTENSION RECEIVED
Dec 18, 2025 EEXT
ASSIGNED TO EXAMINER
Jul 15, 2025 DOCK
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 25, 2025 EXRA
SOU EXTENSION 2 GRANTED
Jun 24, 2025 EX2G
SOU EXTENSION 2 FILED
Jun 24, 2025 EXT2
SOU TEAS EXTENSION RECEIVED
Jun 24, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 16, 2024 EXRA
SOU EXTENSION 1 GRANTED
Dec 16, 2024 EX1G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Dec 12, 2024 AITU
SOU EXTENSION 1 FILED
Nov 12, 2024 EXT1
SOU TEAS EXTENSION RECEIVED
Nov 12, 2024 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jun 25, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 30, 2024 NPUB
PUBLISHED FOR OPPOSITION
Apr 30, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 10, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 25, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 23, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 23, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 23, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Dec 29, 2023 GNRN
NON-FINAL ACTION E-MAILED
Dec 29, 2023 GNRT
NON-FINAL ACTION WRITTEN
Dec 29, 2023 CNRT
ASSIGNED TO EXAMINER
Dec 5, 2023 DOCK
TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED
Jul 14, 2023 TAEA
TEAS VOLUNTARY AMENDMENT RECEIVED
Jul 14, 2023 PARI
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jul 13, 2023 TCCA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Jul 13, 2023 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Jul 13, 2023 COAR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 28, 2023 NWOS
NEW APPLICATION ENTERED
Mar 10, 2023 NWAP